Дифференцированный подход к назначению комбинированных топических стероидов – минимизация риска нежелательных лекарственных реакций

1. Sulzberger MB, Witten VH. Effect of topically applied compound F in
selected dermatoses. J Invest Dermatol 1952; 19: 101–2.
2. Fitzpatrick TB, Griswold HC, Hicks JH. Sodium retention and edema
from percutaneous absorption of fludrocortisone acetate. J Am Med
Assoc 1955; 158: 1149–52.
3. Schafer-Korting M, Kleuser B, Ahmed M et al. Glucocorticoids for
human skin: New aspects of the mechanism of action. Skin Pharmacol
Physiol 2005; 18: 103–14.
4. Goa KL. Clinical pharmacology and pharmacokinetic properties of
topically applied corticosteroids. A review. Drugs 1988; 36 (Suppl. 5):
51–61.
5. Katzung BG, Trevor AJ, Masters SB. Basic and Clinical Pharmacology.
11th ed. New York: McGraw-Hill, 2009; 681–99.
6. Зайчик А.Ш., Чурилов Л.П. Общая патофизиология (с основами
иммунопатологии) Изд. 4-е. СПб.: ЭЛБИ-СПб, 2008.
7. Gilberton EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent
topical corticosteroid use associated with adrenal suppression: clinical
considerations. J Am Acad Dermatol 1998; 38: 318–21.
8. Ermis B, Ors R, Tastekin A, Ozkan B. Cushing's syndrome secondary to
topical corticosteroid abuse. Clin Endocrinol (Oxf) 2003; 58: 795–6.
9. Middleton E, Reed C, Ellis E. (eds.). Allergy: Principles and Practice. St.
Louis: Mosby, 1978.
10. Березов Т.Т., Коровкин Б.Ф. Биологическая химия. Учебник. 3-е
изд. М.: Медицина, 1998.
11. Wang RIH, Sytkowski A, Sherry KR. Relating corticosteroid structure
and function. Drug Ther November 1975; 143–9.
12. Rubin RP. Adrenocorticoid hormones and drugs affecting the adrenal
cortex. In: Craig CR, Stitzel RE, ed. Modern Pharmacology. 4th ed.
Boston/New York/Toronto/London: Little, Brown and Company, 1994;
731–45.
13. Liddle GW, Pechet MM, Bartter FC. Enhancement of biological activities
of glucocorticoids by substitution of halogen atoms in 9a position.
Science 1954; 120: 496–7.
14. Bikowski J, Pillai R, Shroot B. The position not the presence of the
halogen in corticosteroids influences potency and side effects. J Drugs
Dermatol 2006; 5 (2): 125–30.
15. Guzzo C, Lazarus GS, Werth VP. Dermatological pharmacology. In:
Harman JG, Limbird LE, Molinoff PB et al. (eds.). Goodman & Gilman’s
The pharmacological basis of therapeutics, 9th ed.; New York: McGraw-
Hill; 1996; 1593–616.
16. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of
steroid-sparing therapy. J Am Acad Dermatol 2005; 53: 50–8.
17. Niedner R. Die geschichte der topischen kortikoide. Akt Dermatol
1997; 23: 60–4.
18. Fritz KA, Weston WL. Topical glucocorticosteroids. Ann Allergy 1983;
50 (2): 68–76.
19. Leung DYM. The role of Staphylococcus aureus in atopic eczema.
Acta Derm Venereol 2008; Suppl. 216: 21–7.
20. Fleisher AB Jr, Feldman SR. Prescription of high-potency corticosteroid
agents and clotrimazole-betamethasone dipropionate by pediatricians.
Clin Ther 1999; 21 (10): 1725–31.
21. Greenberg HL, Shwayder TA, Bieszk N, Fiveson DP.
Clotrimazole/betamethasone dipropionate: a review of costs and complications
in the treatment of common cutaneous fungal infections.
Pediatric Dermatology 2002; 19 (1): 78–81.
22. Gianotti B. Current treatment guidelines for topical corticosteroids.
Drugs 1988; 36: 9–14.
23. Katz HI, Hien NT, Prawer SE et al. Superpotent topical steroid treatment
of psoriasis vulgaris: clinical efficacy and adrenal function. J Am
Acad Dermatol 1987; 16: 804–11.
24. Hengge UR, Ruzicka T, Schwartz R, Cork MJ. Adverse effects of topical
glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1–15.
25. Wester RC, Maibach HI. Dermatopharmacokinetics in clinical dermatology.
Semin Dermatol 1983; 2: 81–4.
26. Saarni K, Jalkanen M, Hopsu-Havu VK. Effects of five anti-inflammatory
steroids on DNA synthesis by normal skin fibroblasts in vitro.
Arch Dermatol Res 1980; 268 (2): 217–9.
27. Saarni H, Jalkanen M, Hopsu-Havu VK. Effect of five anti-inflammatory
steroids on collagen and glycoaminoglycan synthessis in vitro. Br J
Dermatol 1980; 103 (2): 167–73.
28. FDA Approved Label LOTRISONER Cream LOTRISONER Lotion rev.
May 2009: www.accessdata.fda.gov/drugsatfda_docs/label/2009/
020010s021lbl.pdf
29. Видаль Лекарственные препараты в России: Справочник. М.:
АстраФармСервис, 2009.
30. Rosen T, Elewski BE. Failure of clotrimazole-betamethasone dipropionate
cream in the treatment of Microsporum canis infections. J Am
Acad Dermatol 1995; 32: 1050–1.
31. Smith EB, Breneman DL, Griffith RF et al. Double-blind comparison
of naftifine cream in the treatment of tinea pedis. J Am Acad Dermatol
1992; 26: 125–7.
32. Reynolds RD, Boiko S, Lucky AW. Exacerbation of tinea corporis during
treatment with 1% clotrimazole/0,05% betamethasone dipropionate.
Am J Dis Child 1991; 145: 1224–5.
33. Smith SE, Fleisher AB, Steven FR. Nondermatologists are more likely
than dermatologists to prescribe antifungal/corticosteroid products: An
analysis of office visits for cutaneous fungal infections, 1990–1994. J
Am Acad Dermatol 1998; 39: 43–7.
34. Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Современные
комбинированные средства наружной терапии атопического
дерматита, осложненного вторичной инфекцией. Журнал
«Практика педиатра», 2008 (3): 28–32.
35. Тихомиров А.А., Гамаюнов Б.Н. Сравнительная эффективность
Момата (мометазона фуроата) и гидрокортизона-17-
бутирата в наружной терапии атопического дерматита. Рус.
мед. журн. 16 (18) 1183–90.